South Korea Approved a Protein-based Adult Booster

Novavax, Inc. today announced that partner SK bioscience had received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid™ (NVX-CoV2373), a protein-based booster for active immunization to prevent COVID-19 in adults aged 18 and older.

KFMDS previously approved Nuvaxovid as a primary series in adults aged 18 and older in January 2022 and as a primary series in adolescents aged 12 through 17 in August 2022.

"We are pleased to collaborate with SK bioscience to offer our protein-based vaccine, Nuvaxovid, for use as a booster in adults regardless of previous vaccine history," said Stanley C. Erck, President and Chief Executive Officer, Novavax, in a press release on January 18, 2-23. 

"This is an important step in ensuring broad access to diversified vaccine options."

Novavax' COVID-19 vaccine is authorized as an adult booster in more than 35 countries.

In addition, several other countries have policy recommendations allowing the use of the vaccine as a booster dose.